Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Img-7289
2. Bomedemstat [usan]
3. Y2t4aldeat
4. 1990504-34-1
5. Benzamide, N-((1s)-4-(((1r,2s)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1h-1,2,3-triazol-1-yl)-
6. Unii-y2t4aldeat
7. Bomedemstat [inn]
8. Bomedemstat [who-dd]
9. Chembl4297289
10. Schembl17984236
11. Bdbm425083
12. Who 11114
13. Us10519118, Example 158
14. Db15126
15. Hy-109169
16. Cs-0116355
17. N-((1s)-4-(((1r,2s)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1h-1,2,3-triazol-1-yl)benzamide
18. N-((s)-5-((1r,2s)-2-(4- Fluorophenyl)cyclopropylamino)-1-(4- Methylpiperazin-1-yl)-1-oxopentan-2-yl)-4- (1h-1,2,3-triazol-1-yl)benzamide
19. N-[(2s)-1-(4-(methyl)piperazin-1-yl)-5-[[(1r,2s)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1h-1,2,3-triazol-1-yl)benzamide
| Molecular Weight | 519.6 g/mol |
|---|---|
| Molecular Formula | C28H34FN7O2 |
| XLogP3 | 2.3 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 10 |
| Exact Mass | 519.27580151 g/mol |
| Monoisotopic Mass | 519.27580151 g/mol |
| Topological Polar Surface Area | 95.4 Ų |
| Heavy Atom Count | 38 |
| Formal Charge | 0 |
| Complexity | 779 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
Bomedemstat is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Bomedemstat,Carbamazepine
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 19, 2024
Lead Product(s) : Bomedemstat,Carbamazepine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Bomedemstat is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 19, 2024
Details:
MK-3543 (bomedemstat) is an investigational orally available small molecule that inhibits LSD1. It is under phase 3 clinical development for the treatment of essential thrombocythemia.
Lead Product(s): Bomedemstat,Inapplicable
Therapeutic Area: Hematology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 27, 2024
Lead Product(s) : Bomedemstat,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Merck Starts Phase 3 Trial of Bomedemstat for Essential Thrombocythemia Treatment
Details : MK-3543 (bomedemstat) is an investigational orally available small molecule that inhibits LSD1. It is under phase 3 clinical development for the treatment of essential thrombocythemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 27, 2024
Details:
Bomedemstat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Thrombocythemia, Essential.
Lead Product(s): Bomedemstat,Inapplicable
Therapeutic Area: Hematology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 13, 2024
Lead Product(s) : Bomedemstat,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
Details : Bomedemstat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Thrombocythemia, Essential.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 13, 2024
Details:
Bomedemstat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Thrombocythemia, Essential.
Lead Product(s): Bomedemstat,Inapplicable
Therapeutic Area: Hematology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 08, 2024
Lead Product(s) : Bomedemstat,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Details : Bomedemstat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Thrombocythemia, Essential.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 08, 2024
Details:
MK-3543 (bomedemstat) is an investigational orally available small molecule that inhibits LSD1. It is under phase 3 clinical development for the treatment of essential thrombocythemia.
Lead Product(s): Bomedemstat,Inapplicable
Therapeutic Area: Hematology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 05, 2023
Lead Product(s) : Bomedemstat,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MK-3543 (bomedemstat) is an investigational orally available small molecule that inhibits LSD1. It is under phase 3 clinical development for the treatment of essential thrombocythemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 05, 2023
Details:
Bomedemstat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Thrombocythemia, Essential.
Lead Product(s): Bomedemstat,Inapplicable
Therapeutic Area: Hematology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 12, 2023
Lead Product(s) : Bomedemstat,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Bomedemstat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Thrombocythemia, Essential.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 12, 2023
Details:
Under the acquisition agreement, Merck will strengthens the presence in the growing field of hematology by also acquiring pipeline of Imago, having lead candidate IMG-7289 (bomedemstat), an investigational orally available lysine-specific demethylase 1 (LSD1) inhibitor.
Lead Product(s): Bomedemstat,Inapplicable
Therapeutic Area: Hematology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Merck & Co
Deal Size: $1,350.0 million Upfront Cash: $1,350.0 million
Deal Type: Acquisition January 11, 2023
Lead Product(s) : Bomedemstat,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : $1,350.0 million
Deal Type : Acquisition
Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.
Details : Under the acquisition agreement, Merck will strengthens the presence in the growing field of hematology by also acquiring pipeline of Imago, having lead candidate IMG-7289 (bomedemstat), an investigational orally available lysine-specific demethylase 1 (...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $1,350.0 million
January 11, 2023
Details:
Phase 2 study of IMG-7289 (bomedemstat), an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with ruxolitinib (Jakafi®) in people with myelofibrosis (MF) conducted at the Department of Medicine, Queen Mary Hospital.
Lead Product(s): Bomedemstat,Ruxolitinib Phosphate
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 20, 2022
Lead Product(s) : Bomedemstat,Ruxolitinib Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase 2 study of IMG-7289 (bomedemstat), an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with ruxolitinib (Jakafi®) in people with myelofibrosis (MF) conducted at the Department of Medicine, Queen Mary Hospital.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 20, 2022
Details:
IMG-7289 (bomedemstat), an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, has been generally well-tolerated and has demonstrated significant symptom improvement for patients with myelofibrosis and essential thrombocythemia.
Lead Product(s): Bomedemstat,Venetoclax
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 30, 2022
Lead Product(s) : Bomedemstat,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IMG-7289 (bomedemstat), an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, has been generally well-tolerated and has demonstrated significant symptom improvement for patients with myelofibrosis and essential thrombocythemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 30, 2022
Details:
Under the acquisition agreement, Merck will strengthens the presence in the growing field of hematology by also acquiring pipeline of Imago, having lead candidate bomedemstat (IMG-7289), an investigational orally available lysine-specific demethylase 1 (LSD1) inhibitor.
Lead Product(s): Bomedemstat,Inapplicable
Therapeutic Area: Hematology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Merck & Co
Deal Size: $1,350.0 million Upfront Cash: $1,350.0 million
Deal Type: Acquisition November 21, 2022
Lead Product(s) : Bomedemstat,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : $1,350.0 million
Deal Type : Acquisition
Merck to Acquire Imago BioSciences, Inc.
Details : Under the acquisition agreement, Merck will strengthens the presence in the growing field of hematology by also acquiring pipeline of Imago, having lead candidate bomedemstat (IMG-7289), an investigational orally available lysine-specific demethylase 1 (...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $1,350.0 million
November 21, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
20
PharmaCompass offers a list of Bomedemstat API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Bomedemstat manufacturer or Bomedemstat supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Bomedemstat manufacturer or Bomedemstat supplier.
PharmaCompass also assists you with knowing the Bomedemstat API Price utilized in the formulation of products. Bomedemstat API Price is not always fixed or binding as the Bomedemstat Price is obtained through a variety of data sources. The Bomedemstat Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Bomedemstat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Bomedemstat, including repackagers and relabelers. The FDA regulates Bomedemstat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Bomedemstat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Bomedemstat supplier is an individual or a company that provides Bomedemstat active pharmaceutical ingredient (API) or Bomedemstat finished formulations upon request. The Bomedemstat suppliers may include Bomedemstat API manufacturers, exporters, distributors and traders.
Bomedemstat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Bomedemstat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Bomedemstat GMP manufacturer or Bomedemstat GMP API supplier for your needs.
A Bomedemstat CoA (Certificate of Analysis) is a formal document that attests to Bomedemstat's compliance with Bomedemstat specifications and serves as a tool for batch-level quality control.
Bomedemstat CoA mostly includes findings from lab analyses of a specific batch. For each Bomedemstat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Bomedemstat may be tested according to a variety of international standards, such as European Pharmacopoeia (Bomedemstat EP), Bomedemstat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Bomedemstat USP).
